biostudies-literatureUnknown82(5)Zimmer JA<h4>Importance</h4>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.<h4>Objective</h4>To characterize ARIA in participants treated with donanemab.<h4>Design, setting, and participants</h4>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controJAMA neurology461-469https://www.ebi.ac.uk/biostudies/studies/S-EPMC11894547biostudies-literatureAmyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.PMC11894547Salloway SLauzon SBattioui CBrooks DAKhanna RSims JRArdayfio PWang HZimmer JAAndersen SNery ESMSvaldi DLu MEvans CDBiffi AGreenberg SMSperling RAEngle SESparks JMintun MfalseAmyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.<h4>Importance</h4>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.<h4>Objective</h4>To characterize ARIA in participants treated with donanemab.<h4>Design, setting, and participants</h4>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-contro2025-01-01T00:00:00Z2025 May2026-06-02T19:18:29.235Z2025-04-04T02:51:00.909ZS-EPMC118945474006301510.1001/jamaneurol.2025.0065